# OnCo record paper-gog-281-trametinib-lgsoc-gershenson-lancet-2022 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-gog-281-trametinib-lgsoc-gershenson-lancet-2022/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-gog-281-trametinib-lgsoc-gershenson-lancet-2022" ;
  schema:name "GOG 281/LOGS: trametinib versus standard of care in recurrent low-grade serous ovarian cancer"@en ;
  schema:description "The MEK inhibitor trametinib more than doubled the time to progression compared with chemotherapy or hormone therapy in recurrent low-grade serous ovarian cancer, the first positive randomised trial in this slow-growing, chemotherapy-resistant disease."@en ;
  schema:url <https://onco.cc/key-papers/paper-gog-281-trametinib-lgsoc-gershenson-lancet-2022/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S0140-6736(21)02175-9>, <https://pubmed.ncbi.nlm.nih.gov/35123694/> ;
  schema:sameAs <https://doi.org/10.1016/S0140-6736(21)02175-9> ;
  schema:datePublished "2022"^^xsd:gYear ;
  schema:author "Gershenson DM, Miller A, Brady WE, et al." ;
  onco:cancers <https://onco.cc/cancers/low-grade-serous-ovarian-cancer/> ;
  onco:drugs <https://onco.cc/drugs/trametinib/> ;
  onco:journals <https://onco.cc/journals/lancet/> .